ReposiTrak FQ2 2024 revenue $5.13M (+8% YoY), EPS $0.07 (+17%), dividend raised 10%

ReposiTrak, Inc.

2024-Q2 EPS reported $0.14 revenue$10,185,863

Revenue $5.13M (+8% YoY); recurring revenue 99% of total; GAAP net income $1.45M (+15%).
Diluted EPS $0.07 (+17% from $0.06); net income to common shareholders $1.30M (+17%).
Quarterly cash dividend increased 10% to $0.0165/share ($0.066 annual), starting Dec 2023.
Repurchased 22k common shares at avg $8.79; bought back 70k preferred shares for $750k.
Cash $23.25M; no debt; accelerating traceability customer onboarding with FDA mandate.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ReposiTrak, Inc. reported quarter ended December 31, 2023 results: revenue $5.13 million, net income $1.45 million, EPS $0.07 per diluted share.

Period: quarter ended December 31, 2023
Revenue: $5.13 million
Net income: $1.45 million
EPS: $0.07 per diluted share
Result: reported results

Exact text from the filing

financial results for the second fiscal quarter (“FQ2 2024”) ended December 31, 2023. Second Quarter Financial Highlights: ● Second quarter total revenue increased 8% to $5.13 million from $4.75 million. ● Recurring revenue increased 8%, net of the planned elimination of high-touch, low-opportunity revenue, to $5.13 million from $4.74 million, representing

View on SEC.gov

Browse all earnings releases →

ReposiTrak, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-004622

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.